Is Pembrolizumab on the market?

Pembrolizumab was first approved by the U.S. Food and Drug Administration (FDA) on September 4, 2014 for the treatment of metastatic malignant melanoma, becoming the first approved PD-1 therapeutic drug. Since its initial approval, pembrolizumab has been approved to treat a variety of cancers, including non-small cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin lymphoma.

Pembrolizumab is sold under the trade name Keytruda after it is launched. The active ingredient Pembrolizumab in Pembrolizumab can effectively improve the survival rate or delay the progression of the disease in patients with advanced cancer or cancer that has spread or recurred or cannot be surgically removed. In some patients, the tumor must produce a certain level of PD-L1, or must be identified as MSH-I or dMMR, for the drug to be effective. Pembrolizumab was also effective in preventing the recurrence of melanoma and kidney cancer in patients who had undergone surgery, and improved outcomes for triple-negative breast cancer patients who took pembrolizumab before and after surgery.

PembrolizumabThe original drug is already on the market in China. SpecificationsThe price per box of 100mg/4ml may be around RMB 15,000. This drug is a strictly controlled drug and has not yet been included in medical insurance. Pembrolizumab The price of the European version of the original drug 100mg/4ml per box may be around RMB 25,000, and the price of the Turkish version of 100mg/4ml per box may be around 10,000 RMB (the price may fluctuate due to the exchange rate). The ingredients of the original drugs at home and abroad are basically the same, and they are expensive. There are currently no generic versions of Pembrolizumab available overseas.